TY - JOUR
T1 - Structure, Function, and Applications of the Georgetown–Einstein (GE) Breast Cancer Simulation Model
AU - Schechter, Clyde B.
AU - Near, Aimee M.
AU - Jayasekera, Jinani
AU - Chandler, Young
AU - Mandelblatt, Jeanne S.
N1 - Funding Information:
Departments of Family and Social Medicine and Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA (CBS); and Department of Oncology, Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC, USA (AMN, JJ, YC, JSM). Financial support for this study was provided in part by grants numbers U01CA199218, U01CA152958, U01CA088283 from the National Cancer Institute; Dr. Chandler’s time was also supported, in part, by ACS MCGAWD-4442502/GR410195. The authors are responsible for the research and had full independence in designing the study, interpreting the data, writing, and publishing the report.
Publisher Copyright:
© 2017, © The Author(s) 2017.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Background. The Georgetown University-Albert Einstein College of Medicine breast cancer simulation model (Model GE) has evolved over time in structure and function to reflect advances in knowledge about breast cancer, improvements in early detection and treatment technology, and progress in computing resources. This article describes the model and provides examples of model applications. Methods. The model is a discrete events microsimulation of single-life histories of women from multiple birth cohorts. Events are simulated in the absence of screening and treatment, and interventions are then applied to assess their impact on population breast cancer trends. The model accommodates differences in natural history associated with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) biomarkers, as well as conventional breast cancer risk factors. The approach for simulating breast cancer natural history is phenomenological, relying on dates, stage, and age of clinical and screen detection for a tumor molecular subtype without explicitly modeling tumor growth. The inputs to the model are regularly updated to reflect current practice. Numerous technical modifications, including the use of object-oriented programming (C++), and more efficient algorithms, along with hardware advances, have increased program efficiency permitting simulations of large samples. Results. The model results consistently match key temporal trends in US breast cancer incidence and mortality. Conclusion. The model has been used in collaboration with other CISNET models to assess cancer control policies and will be applied to evaluate clinical trial design, recurrence risk, and polygenic risk-based screening.
AB - Background. The Georgetown University-Albert Einstein College of Medicine breast cancer simulation model (Model GE) has evolved over time in structure and function to reflect advances in knowledge about breast cancer, improvements in early detection and treatment technology, and progress in computing resources. This article describes the model and provides examples of model applications. Methods. The model is a discrete events microsimulation of single-life histories of women from multiple birth cohorts. Events are simulated in the absence of screening and treatment, and interventions are then applied to assess their impact on population breast cancer trends. The model accommodates differences in natural history associated with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) biomarkers, as well as conventional breast cancer risk factors. The approach for simulating breast cancer natural history is phenomenological, relying on dates, stage, and age of clinical and screen detection for a tumor molecular subtype without explicitly modeling tumor growth. The inputs to the model are regularly updated to reflect current practice. Numerous technical modifications, including the use of object-oriented programming (C++), and more efficient algorithms, along with hardware advances, have increased program efficiency permitting simulations of large samples. Results. The model results consistently match key temporal trends in US breast cancer incidence and mortality. Conclusion. The model has been used in collaboration with other CISNET models to assess cancer control policies and will be applied to evaluate clinical trial design, recurrence risk, and polygenic risk-based screening.
KW - breast cancer
KW - simulation modeling
UR - http://www.scopus.com/inward/record.url?scp=85040637440&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040637440&partnerID=8YFLogxK
U2 - 10.1177/0272989X17698685
DO - 10.1177/0272989X17698685
M3 - Article
C2 - 29554462
AN - SCOPUS:85040637440
SN - 0272-989X
VL - 38
SP - 66S-77S
JO - Medical Decision Making
JF - Medical Decision Making
IS - 1_suppl
ER -